Dunhill Financial’s Denali Therapeutics DNLI Stock Holding History

Dunhill Financial’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53	Hold	2	–	–	﹤0.01%	1502
2026 Q1	$40	Hold	2	–	–	﹤0.01%	1661
2025 Q4	$35	Buy	+2	New	+$34	﹤0.01%	1772

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dunhill Financial's DNLI Position: Q2 2026 in Review

Dunhill Financial held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 2 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Dunhill Financial first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Dunhill Financial held 2 shares of Denali Therapeutics worth $53 as of Q2 2026.
Dunhill Financial left its Denali Therapeutics share count unchanged in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1502 holding.
Dunhill Financial first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.